References
- Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81:835–848.
- Renault F, Flores-Guevara R, Renaud C, et al. Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr. 2009;98:1500–1503.
- Faculty of Sexual & Reproductive Healthcare. Drug interaction with hormonal contraception; January 2017 [cited 2019 Jan]. Available from: https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/
- Faculty of Sexual & Reproductive Healthcare. Switching or starting methods of contraception. Produced by Clinical Effectiveness Unit (CEU) of the FSRH. Feb 2017 (Amended Aug 2019), Rev Feb 2020.
- World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
- Moreau C, Trussell J. Results from pooled phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012;86(6):673–680.